RA Capital Management led a $115m Series B round in ILiAD Biotechnologies.

RA Capital Management, a multi-stage investment manager, led a $115m Series B round in ILiAD Biotechnologies, a clinical-stage biotech company, with participation from Janus Henderson Investors and BNP Paribas Asset Management Alts. “Today’s financing reflects the urgent need for better pertussis vaccines, the scientific rigor and operational discipline of our team, and the extraordinary potential BPZE1 holds to improve global public health. We are grateful to RA Capital for their diligent efforts to lead the round, to Janus and BNPP AM Alts for their active partnership during the financing process, and to existing investors and all those who came before in support of our mission to eradicate pertussis disease once and for all,” Keith Rubin, ILiAD MD, Founder and CEO.